SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001567619-19-012846
Filing Date
2019-06-05
Accepted
2019-06-05 17:50:54
Documents
2
Period of Report
2019-05-20

Document Format Files

Seq Description Document Type Size
1 FORM 3 doc1.html 3  
1 FORM 3 doc1.xml 3 4081
2 EXHIBIT 24.1 - POWER OF ATTORNEY poa_smith.htm EX-24.1 6951
  Complete submission text file 0001567619-19-012846.txt   12775
Mailing Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Issuer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O KALVISTA PHARMACEUTICALS, INC. 55 CAMBRIDGE PARKWAY, SUITE 901E CAMBRIDGE MA 02142
Business Address
Smith Michael David (Reporting) CIK: 0001777800 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36830 | Film No.: 19880881